SynthesisBMC cancer2026
Human endogenous retroviruses as immune-related prognostic biomarkers in pancreatic cancer.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman endogenous retroviruses (HERVs) may modulate antitumor immunity and prognosis in pancreatic cancer (PC), but reported findings remain heterogeneous.
methodsA systematic review was conducted according to PRISMA guidelines. PubMed/MEDLINE and grey literature were searched for studies reporting HERV expression in PC. Extracted data included HERV family and genomic region, detection methods, biological specimens, immune correlations, clinicopathologic associations, and survival outcomes.
resultsEleven studies were included, reporting 1,085 PC cases among 9,241 cancer patients. HERV-H was evaluated in 6 studies, HERV-K in 3, and 2 studies did not specify family. Elements included env sequences (3 studies), envelope proteins (2), LTR sequences (6), and LTR-derived proteins (HHLA2 (5). Detection methods comprised RNA-seq (n = 7 studies), PCR/qPCR (n = 7), immunohistochemistry (n = 6), western blot (n = 4), and ELISA (n = 4). HERV detection ranged from 16.7% to ~ 80%, varying with the sequence and laboratory method. Immune correlations were described in 7 studies, including associations with CD8⁺ T-cell infiltration, cytokines (IL-2, TNF-α, IFN-γ), PD-1/PD-L1, and anti-HERV antibodies. Overall survival was reported in 6 studies, with both adverse (HR 1.26-2.24) and favourable (HR 0.47-0.66) associations reported, particularly for HERV-H derived LTR products (HHLA2).
conclusionsHERVs exhibit frequent, target-dependent expression patterns that trigger proinflammatory activation. Within these families, HERV-H derived LTR elements, specifically HHLA2, demonstrate the most consistent correlation with increased T-cell infiltration and favorable survival, supporting their potential as prognostic biomarkers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.